The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies
Wujood Khayat1,2, Christian Lehmann1,3,4
1Department of Physiology and Biophysics, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Metabolites
|June 23, 2022
Summary
Cannabinoid use impacts blood coagulation, with controversial effects on clot formation. Further research into the endogenous cannabinoid system (ECS) and its interaction with coagulation is crucial for developing new coagulopathy treatments.
Area of Science:
- Pharmacology
- Hematology
- Neuroscience
Background:
- Coagulopathy, or abnormal blood coagulation, is a frequent complication of various diseases.
- Imbalances in coagulation and fibrinolysis systems cause impaired blood clot formation, leading to ischemia or hemorrhage.
- Emerging evidence links cannabinoid use to coagulopathy, implicating the endogenous cannabinoid system (ECS).
Purpose of the Study:
- To review the endogenous cannabinoid system (ECS).
- To discuss conflicting reports on cannabinoid effects on blood coagulation (anticoagulatory vs. procoagulatory).
- To explore potential mechanisms behind these effects and their therapeutic implications for coagulopathies.
Main Methods:
- Literature review of studies on cannabinoid use and blood coagulation.
- Analysis of evidence for both anticoagulant and procoagulant effects of cannabinoids.
- Examination of the role of the endogenous cannabinoid system (ECS) in hemostasis.
Main Results:
- Cannabinoid use is associated with altered blood coagulation, but effects are debated.
- Evidence suggests both inhibition (anticoagulatory) and promotion (procoagulatory) of blood clotting by cannabinoids.
- The endogenous cannabinoid system (ECS) appears to play a role in modulating coagulation.
Conclusions:
- The precise impact of cannabinoids on blood coagulation remains controversial.
- Understanding the interaction between the ECS and coagulation pathways is essential.
- Further research may lead to novel therapeutic strategies for treating coagulopathies.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
884
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
884
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.1K
01:29Venous Thrombosis III: Interprofessional Care
21
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
21
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
365
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
365
01:09Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K